Home Cart Sign in  
Chemical Structure| 897016-82-9 Chemical Structure| 897016-82-9

Structure of Tirbanibulin
CAS No.: 897016-82-9

Chemical Structure| 897016-82-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

KX2-391 is an inhibitor of Src with IC50 of 9 nM-60 nM in cancer cells. It is the first clinical and peptidomimetic class Src inhibitor.

Synonyms: KX-01; KX2-391

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tirbanibulin

CAS No. :897016-82-9
Formula : C26H29N3O3
M.W : 431.53
SMILES Code : O=C(NCC1=CC=CC=C1)CC2=NC=C(C3=CC=C(OCCN4CCOCC4)C=C3)C=C2
Synonyms :
KX-01; KX2-391
MDL No. :MFCD18633218
InChI Key :HUNGUWOZPQBXGX-UHFFFAOYSA-N
Pubchem ID :23635314

Safety of Tirbanibulin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tirbanibulin

RTK

Isoform Comparison

Biological Activity

Target
  • Src

    Src (Hep 3B), GI50:26 nM

    Src (HuH7), GI50:13 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-468 10-250 nM 48 h KX-01 inhibited the growth of MDA-MB-468 cells. PMC3462004
Ba/F3 cells 1 µM 1 h Evaluate the inhibitory effect of KX2-391 on FLT3-ITD cells PMC8255005
MDA-MB-157 10-250 nM 48 h KX-01 inhibited the growth of MDA-MB-157 cells. PMC3462004
MDA-MB-231 10-250 nM 48 h KX-01 inhibited the growth of MDA-MB-231 cells. PMC3462004
Pa16C 80 nM 24 h To evaluate the effect of Tirbanibulin on MYC protein levels and phosphorylation PMC8340308
H460 cells 100 nM 16 h KXO1 induced G2/M phase cell cycle arrest PMC6885616
HepG2 cells 50 nM 16 h KXO1 induced G2/M phase cell cycle arrest PMC6885616
HeLa cells 30 nM 16 h KXO1 inhibited tubulin polymerization and induced G2/M phase cell cycle arrest PMC6885616
Human monocyte-derived macrophages (HMDM) 0.33 μM 15 h Tirbanibulin significantly enhanced the killing of VRE by HMDM. PMC11091880
RAW264.7 macrophages 0.33 μM 15 h Tirbanibulin stimulated macrophage killing of bacteria, significantly reducing intracellular VRE CFU. PMC11091880
HeLa cells 12.5, 25, 50, 100 nM 16 h KXO1 induced G2/M phase cell cycle arrest, further confirming that KXO1 is a strong tubulin inhibitor. PMC6885616
HeLa cells 30 nM 16 h KXO1 inhibited tubulin polymerization, confirming that KXO1 is a strong tubulin depolymerization agent. PMC6885616

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mouse Pancreatic cancer model Oral 15 mg/kg Daily for 14 days To evaluate the inhibitory effect of Tirbanibulin in combination with ERK inhibitor on pancreatic cancer growth PMC8340308
Mice Wound infection model Intraperitoneal injection 5 mg/kg Single dose Tirbanibulin significantly reduced VRE CFU in wounds, demonstrating its antibacterial efficacy in vivo. PMC11091880
Mice FLT3-ITD-F691L leukemia model Oral 10 mg/kg Once daily for 10 days Evaluate the therapeutic effect of KX2-391 on FLT3-ITD-F691L leukemia model, significantly prolonging survival PMC8255005
BALB/c nude mice Lung and liver metastasis models Oral 15 mg/kg Daily for 9 weeks To evaluate the inhibitory effects of combined therapy with BLU-554 and KX2-391 on ELF4-mediated CRC metastasis. The results showed that combined treatment significantly inhibited lung and liver metastasis and prolonged the survival of mice. PMC10008733
Nude mice MDA-MB-231 tumor xenograft model Oral 1 mg/kg and 5 mg/kg Twice daily for 28 days KX-01 significantly inhibited the growth of MDA-MB-231 tumors. PMC3462004

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01074138 Bone-Metastatic, Castration-Re... More >>sistant Prostate Cancer Less << PHASE2 COMPLETED 2025-10-12 University of Chicago, Chicago... More >>, Illinois, 60637, United States|Johns Hopkins University, Baltimore, Maryland, 21205, United States|Wayne State University-Karmanos Cancer Center, Detroit, Michigan, 48201, United States|University of Washington, Seattle, Washington, 98109, United States|University of Wisconsin, Madison, Wisconsin, 53792, United States Less <<
NCT01397799 Acute Myelogenous Leukemia PHASE1 COMPLETED 2025-07-14 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263, United States|Weill Cornell Medical College, New York, New York, 10065, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States Less <<
NCT00658970 Solid Tumors|Lymphoma PHASE1 COMPLETED 2025-05-11 Fox Chase Cancer Center, Phila... More >>delphia, Pennsylvania, 19111, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT05900258 Actinic Keratosis PHASE4 COMPLETED 2023-11-13 Medizinische Universit?t Graz,... More >> Graz, Austria Less <<
NCT05260073 Keratosis, Actinic COMPLETED 2023-03-07 Almirall Investigational Site ... More >>1, Charleston, South Carolina, 29401, United States Less <<
NCT06026358 Actinic Keratoses PHASE4 WITHDRAWN 2025-12-24 -
NCT06112522 Cell Carcinoma PHASE2 RECRUITING 2025-12-01 CHU de Nice - H?pital de l'Arc... More >>het, Nice, Alpes-maritimes, 06200, France Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.32mL

0.46mL

0.23mL

11.59mL

2.32mL

1.16mL

23.17mL

4.63mL

2.32mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories